Pharmacovigilance: Rethinking literature monitoring and review
Pharmacovigilance: Rethinking literature
monitoring and review
5 Strategies to Streamline the Process and Ease the Pain
Pharmacovigilance is defined as
the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.
Under that umbrella, government agencies in the United States, the European Union and other parts of the world have developed diverse and increasingly complex regulatory requirements. A key component of those requirements is literature monitoring and review—that is, systematic screening of scientific journals for documented or possible adverse drug reactions (ADRs)—the scope of which continues to expand. Importantly, shortcomings in this arena may be indicative of gaps in other areas of a company’s pharmacovigilance processes, or detract from an otherwise effective system that is already in place.
Explore current and emerging literature monitoring and review requirements, which have global implications, including five ways to make literature monitoring and review more comprehensive and manageable.
Please fill in the form on the right to access the complimentary white paper
Pharmacovigilance: Rethinking literature monitoring and review.
To access the complementary white paper 'Pharmacovigilance: Rethinking literature monitoring and review', please fill in the form below.
By submitting this form you also agree to receive information relevant to your interests from Elsevier B.V. and its affiliates worldwide. You can opt-out at any time by following the instructions given in the email messages you receive.
Elsevier R&D Solutions supporting 'Pharmacovigilance: Rethinking literature monitoring and review'
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.